Leuprolide Mesylate

Phase 3Small molecule

FForesee Pharmaceuticals Co., Ltd.

Leuprolide Mesylate is one of 78 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Central Precocious PubertyActive, not recruiting

Prostate CancerActive, not recruiting

Prostate CarcinomaPhase 3

Active, not recruiting

Central Precocious PubertyPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Leuprolide Mesylate

FForesee Pharmaceuticals Co., Ltd.

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Central precocious puberty1 trial

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Active, not recruiting·FForesee Pharmaceuticals Co., Ltd.·Phase 3·NCT05493709·93 enrolled

Prostate Cancer1 trial

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Completed·FForesee Pharmaceuticals Co., Ltd.·Phase 3·NCT03261999·144 enrolled

Prostate Carcinoma1 trial

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Completed·FForesee Pharmaceuticals Co., Ltd.·Phase 3·NCT02234115·137 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Leuprolide Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leuprolide Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leuprolide Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Foresee Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForesee Pharmaceuticals Co., Ltd.

Leuprolide Mesylate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Central precocious puberty1 trial

Prostate Cancer1 trial

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News